The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Crypto: A New Asset Class?
What’s Ahead for Inflation?
Copper is the New Oil
Fostering Innovation Within Companies: An Inside Look at GS Accelerate
The Exit Interview: Jake Siewert on the Media, Communications and the Role of Podcasts
Why Global Insurers Are Leaning Into Risk
Markets Update: Emerging Markets’ Next Phase
The Evolution of LGBTQ+ Rights in Japan: A Conversation With GS Advocates
What’s Ahead for the U.S. Dollar?
Whenever, Wherever: Seamless Commerce is the Future of Retail
What’s Behind the Record Level of Equity Issuance?
Top of Mind: Reflation Risk
Outlook for Equity Markets
A Guide to Bubbles and Why We Are Not in One
How Supply-Chain Disruptions Are Impacting Inflation
Special Episode: What the American Rescue Plan Means for the Economy, Markets, Corporations and Investors
The State of U.S. Corporate Pensions
The Case for Investing in Black Women
Higher Rates Unlikely to Derail the US Housing Market Strength
How Hedge Funds are Navigating a Volatile Market
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money